Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2851622 | American Heart Journal | 2007 | 11 Pages |
Abstract
Carvedilol use at the time of HF hospital discharge is well tolerated, improves treatment rates, and is associated with an early survival benefit. These findings provide further support for guideline recommendations that carvedilol or other evidence-based β blocker should be initiated before hospital discharge in stable patients with HF and LVSD.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gregg C. MD, William T. MD, Nancy M. RN, PhD, Wendy Gattis PharmD, Mihai MD, Barry H. MD, Christopher M. MD, Jie Lena MS, Clyde MD, James B. MD,